HomeCompareKRDXF vs ABBV

KRDXF vs ABBV: Dividend Comparison 2026

KRDXF yields 2.27% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KRDXF wins by $12.5K in total portfolio value· pulled ahead in Year 10
10 years
KRDXF
KRDXF
● Live price
2.27%
Share price
$328.47
Annual div
$7.45
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$114.8K
Annual income
$42,752.63
Full KRDXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KRDXF vs ABBV

📍 KRDXF pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRDXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRDXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KRDXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRDXF
Annual income on $10K today (after 15% tax)
$192.82/yr
After 10yr DRIP, annual income (after tax)
$36,339.74/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KRDXF beats the other by $15,283.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRDXF + ABBV for your $10,000?

KRDXF: 50%ABBV: 50%
100% ABBV50/50100% KRDXF
Portfolio after 10yr
$108.6K
Annual income
$33,762.20/yr
Blended yield
31.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KRDXF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
11.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRDXF buys
0
ABBV buys
0
No recent congressional trades found for KRDXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRDXFABBV
Forward yield2.27%3.06%
Annual dividend / share$7.45$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.3%40.6%
Portfolio after 10y$114.8K$102.3K
Annual income after 10y$42,752.63$24,771.77
Total dividends collected$87.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: KRDXF vs ABBV ($10,000, DRIP)

YearKRDXF PortfolioKRDXF Income/yrABBV PortfolioABBV Income/yrGap
1$11,036$336.42$11,550$430.00$514.00ABBV
2$12,324$514.59$13,472$627.96$1.1KABBV
3$13,983$796.39$15,906$926.08$1.9KABBV
4$16,214$1,252.38$19,071$1,382.55$2.9KABBV
5$19,361$2,012.75$23,302$2,095.81$3.9KABBV
6$24,048$3,331.21$29,150$3,237.93$5.1KABBV
7$31,466$5,734.56$37,536$5,121.41$6.1KABBV
8$44,068$10,399.65$50,079$8,338.38$6.0KABBV
9$67,339$20,186.50$69,753$14,065.80$2.4KABBV
10← crossover$114,806$42,752.63$102,337$24,771.77+$12.5KKRDXF

KRDXF vs ABBV: Complete Analysis 2026

KRDXFStock

Kardex Holding AG provides intralogistics solutions; and supplies automated storage solutions and materials handling systems worldwide. The company operates in two segments, Kardex Remstar and Kardex Mlog. The Kardex Remstar segment develops, produces, and maintains dynamic storage and retrieval systems. The Kardex Mlog segment offers integrated material handling systems and automated high bay warehouses. The company provides vertical buffer, carousel, and lift, as well as horizontal carousel modules; heavy duty units; office solutions; stacker cranes; AutoStore; pick and place robotics; conveyor systems; software and control solutions; and accessories. Its products are used in automated storage and retrieval systems, buffering and sequencing, order fulfillment, controlled environment, document storage, and general contractor applications. Kardex Holding AG is headquartered in Zurich, Switzerland.

Full KRDXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KRDXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRDXF vs SCHDKRDXF vs JEPIKRDXF vs OKRDXF vs KOKRDXF vs MAINKRDXF vs JNJKRDXF vs MRKKRDXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.